

Pekka MÄnnistö

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6562642/publications.pdf>

Version: 2024-02-01

323
papers

10,566
citations

38742

50
h-index

56724

83
g-index

328
all docs

328
docs citations

328
times ranked

9500
citing authors

#	ARTICLE	IF	CITATIONS
1	Catechol-O-Methyltransferase. , 2021, , 414-419.		0
2	Subacute administration of both methcathinone and manganese causes basal ganglia damage in mice resembling that in methcathinone abusers. <i>Journal of Neural Transmission</i> , 2020, 127, 707-714.	2.8	4
3	Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson's Disease. <i>Neuroscience</i> , 2018, 374, 250-263.	2.3	27
4	Delayed O-methylation of L-DOPA in MB-COMT-deficient mice after oral administration of L-DOPA and carbidopa. <i>Xenobiotica</i> , 2018, 48, 325-331.	1.1	2
5	Copy number elevation of 22q11.2 genes arrests the developmental maturation of working memory capacity and adult hippocampal neurogenesis. <i>Molecular Psychiatry</i> , 2018, 23, 985-992.	7.9	22
6	Mechanism of Action of Prolyl Oligopeptidase (PREP) in Degenerative Brain Diseases: Has Peptidase Activity Only a Modulatory Role on the Interactions of PREP with Proteins?. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 27.	3.4	38
7	Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action. <i>ENeuro</i> , 2017, 4, ENEURO.0117-16.2017.	1.9	47
8	Deficiency of prolyl oligopeptidase in mice disturbs synaptic plasticity and reduces anxiety-like behaviour, body weight, and brain volume. <i>European Neuropsychopharmacology</i> , 2016, 26, 1048-1061.	0.7	25
9	Elimination of extracellular dopamine in the medial prefrontal cortex of conscious mice analysed using selective enzyme and uptake inhibitors. <i>Journal of Physiology and Pharmacology</i> , 2016, 67, 301-9.	1.1	7
10	Generation of membrane-bound catechol-O-methyl transferase deficient mice with distinct sex dependent behavioral phenotype. <i>Journal of Physiology and Pharmacology</i> , 2016, 67, 827-842.	1.1	8
11	COMT gene locus. <i>Pain</i> , 2015, 156, 2072-2083.	4.2	28
12	Synthesis and biological evaluation of novel 123I-labeled 4-(4-iodophenyl)butanoyl-L-prolyl-(2S)-pyrrolidines for imaging prolyl oligopeptidase in vivo. <i>European Journal of Medicinal Chemistry</i> , 2014, 79, 436-445.	5.5	2
13	The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse. <i>Neurobiology of Disease</i> , 2014, 68, 1-15.	4.4	75
14	Epistasis between polymorphisms in COMT, ESR1, and GCH1 influences COMT enzyme activity and pain. <i>Pain</i> , 2014, 155, 2390-2399.	4.2	59
15	CNS Catecholamine Metabolism – Emerging Concepts. , 2014, , 67.		0
16	Are Transglutaminase 2 Inhibitors Able to Reduce Gliadin-Induced Toxicity Related to Celiac Disease? A Proof-of-Concept Study. <i>Journal of Clinical Immunology</i> , 2013, 33, 134-142.	3.8	43
17	High correlation between in vivo [123I]²-CIT SPECT/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions induced by 6-OHDA in rats. <i>EJNMMI Research</i> , 2013, 3, 46.	2.5	25
18	Alteration of prolyl oligopeptidase and activated ²-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome. <i>Biochemical Pharmacology</i> , 2013, 85, 1783-1794.	4.4	20

#	ARTICLE	IF	CITATIONS
19	Prolyl oligopeptidase colocalizes with α -synuclein, β -amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases. <i>Neuroscience</i> , 2013, 242, 140-150.	2.3	49
20	Comparison of motor performance, brain biochemistry and histology of two A30P α -synuclein transgenic mouse strains. <i>Neuroscience</i> , 2013, 231, 157-168.	2.3	11
21	Effects of Catechol-O-Methyltransferase Deficiency on the Reinforcing Effects of Cocaine (an) Tj ETQq1 1 0.784314 rrgBT /Overlock 100	0.4	0
22	Gene therapy with α -AAV β -CDNF provides functional benefits in a rat model of Parkinson's disease. <i>Brain and Behavior</i> , 2013, 3, 75-88.	2.2	72
23	Catechol-O-Methyltransferase (COMT) Protein Expression and Activity after Dopaminergic and Noradrenergic Lesions of the Rat Brain. <i>PLoS ONE</i> , 2013, 8, e61392.	2.5	15
24	Distribution of Prolyl Oligopeptidase in Human Peripheral Tissues and in Ovarian and Colorectal Tumors. <i>Journal of Histochemistry and Cytochemistry</i> , 2012, 60, 706-715.	2.5	37
25	Catechol-O-methyltransferase gene polymorphism and chronic human pain. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 673-691.	1.5	134
26	Unpredictable Rotational Responses to L-Dopa in the Rat Model of Parkinson's Disease: the Role of L-Dopa Pharmacokinetics and Striatal Dopamine Depletion. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 110, 162-170.	2.5	6
27	A prolyl oligopeptidase inhibitor, KYP2047, reduces α -synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. <i>British Journal of Pharmacology</i> , 2012, 166, 1097-1113.	5.4	94
28	Strong preferences of dopamine and L-DOPA towards lipid head group: importance of lipid composition and implication for neurotransmitter metabolism. <i>Journal of Neurochemistry</i> , 2012, 122, 681-690.	3.9	51
29	Molecular dynamics, crystallography and mutagenesis studies on the substrate gating mechanism of prolyl oligopeptidase. <i>Biochimie</i> , 2012, 94, 1398-1411.	2.6	47
30	Four day inhibition of prolyl oligopeptidase causes significant changes in the peptidome of rat brain, liver and kidney. <i>Biochimie</i> , 2012, 94, 1849-1859.	2.6	20
31	Advanced brain dopamine transporter imaging in mice using small-animal SPECT/CT. <i>EJNMMI Research</i> , 2012, 2, 55.	2.5	3
32	Different Interactions of Prolyl Oligopeptidase and Neurotensin in Dopaminergic Function of the Rat Nigrostriatal and Mesolimbic Pathways. <i>Neurochemical Research</i> , 2012, 37, 2033-2041.	3.3	11
33	A Transient Inhibition and Permanent Lack of Catechol-O-Methyltransferase have Minor Effects on Feeding Pattern of Female Rodents. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 110, 307-313.	2.5	4
34	Minocycline protects SH-SY5Y cells from 6-hydroxydopamine by inhibiting both caspase-dependent and -independent programmed cell death. <i>Journal of Neuroscience Research</i> , 2012, 90, 682-690.	2.9	21
35	Sequential Expression, Activity and Nuclear Localization of Prolyl Oligopeptidase Protein in the Developing Rat Brain. <i>Developmental Neuroscience</i> , 2011, 33, 38-47.	2.0	12
36	Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats. <i>European Journal of Pain</i> , 2011, 15, 732-740.	2.8	9

#	ARTICLE	IF	CITATIONS
37	Constitutive Ret signaling is protective for dopaminergic cell bodies but not for axonal terminals. <i>Neurobiology of Aging</i> , 2011, 32, 1486-1494.	3.1	18
38	Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GDNF in astroglia. <i>Neuropharmacology</i> , 2011, 61, 574-582.	4.1	84
39	Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo. <i>Neuroscience</i> , 2011, 192, 550-563.	2.3	32
40	Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. <i>Experimental Neurology</i> , 2011, 228, 99-108.	4.1	118
41	Association of Prolyl Oligopeptidase with Conventional Neurotransmitters in the Brain. <i>CNS and Neurological Disorders - Drug Targets</i> , 2011, 10, 311-318.	1.4	6
42	Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A. <i>Clinical and Experimental Immunology</i> , 2011, 164, 127-136.	2.6	43
43	Prolyl oligopeptidase induces angiogenesis both <i>in vitro</i> and <i>in vivo</i> in a novel regulatory manner. <i>British Journal of Pharmacology</i> , 2011, 163, 1666-1678.	5.4	48
44	Effects of Diverse Psychopharmacological Substances on the Activity of Brain Prolyl Oligopeptidase. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 46-54.	2.5	4
45	Effect of Genetic Modifications in the Synaptic Dopamine Clearance Systems on Addiction-like Behaviour in Mice. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 2-8.	2.5	12
46	Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides. <i>CNS and Neurological Disorders - Drug Targets</i> , 2011, 10, 319-326.	1.4	12
47	Complex estrogenic regulation of catechol-O-methyltransferase (COMT) in rats. <i>Journal of Physiology and Pharmacology</i> , 2011, 62, 483-90.	1.1	23
48	Are genetic variants of COMT associated with addiction?. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 717-741.	1.5	57
49	Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 53, 1489-1498.	2.4	4
50	Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice. <i>Psychopharmacology</i> , 2010, 211, 389-401.	3.1	29
51	Sample purification improves the analysis of nonviral in vivo gene transfection. <i>Plasmid</i> , 2010, 63, 27-30.	1.4	2
52	Inhibitors of catechol-O-methyltransferase sensitize mice to pain. <i>British Journal of Pharmacology</i> , 2010, 161, 1553-1565.	5.4	17
53	Distribution of catechol-O-methyltransferase (COMT) proteins and enzymatic activities in wild-type and soluble COMT deficient mice. <i>Journal of Neurochemistry</i> , 2010, 113, 1632-1643.	3.9	87
54	Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. <i>Journal of Neurochemistry</i> , 2010, 114, 1745-1755.	3.9	149

#	ARTICLE	IF	CITATIONS
55	Different Effects of Scopolamine and Inhibition of Prolyl Oligopeptidase on Mnemonic and Motility Functions of Young and 8- to 9-Month-Old Rats in the Radial-Arm Maze. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 106, 280-287.	2.5	15
56	Degradation of coeliac disease-inducing rye secalin by germinating cereal enzymes: diminishing toxic effects in intestinal epithelial cells. <i>Clinical and Experimental Immunology</i> , 2010, 161, 242-249.	2.6	37
57	Catechol-O-Methyltransferase and Pain. <i>International Review of Neurobiology</i> , 2010, 95, 227-279.	2.0	53
58	Distribution and Functions of Catechol-O-Methyltransferase Proteins. <i>International Review of Neurobiology</i> , 2010, 95, 29-47.	2.0	22
59	Biochemistry and Pharmacology of Catechol-O-Methyltransferase Inhibitors. <i>International Review of Neurobiology</i> , 2010, 95, 73-118.	2.0	28
60	Issues About the Physiological Functions of Prolyl Oligopeptidase Based on Its Discordant Spatial Association With Substrates and Inconsistencies Among mRNA, Protein Levels, and Enzymatic Activity. <i>Journal of Histochemistry and Cytochemistry</i> , 2009, 57, 831-848.	2.5	59
61	Over-expression of a human chromosome 22q11.2 segment including TXNRD2, COMT and ARVCF developmentally affects incentive learning and working memory in mice. <i>Human Molecular Genetics</i> , 2009, 18, 3914-3925.	2.9	53
62	The role of PEI structure and size in the PEI/liposome-mediated synergism of gene transfection. <i>Plasmid</i> , 2009, 61, 15-21.	1.4	26
63	Pharmacokinetics of Clofibrate and Chlorophenoxy Isobutyric Acid. I. Cross-over Studies on Human Volunteers. <i>Acta Pharmacologica Et Toxicologica</i> , 2009, 36, 353-365.	0.0	15
64	Sex-dependent compensated oxidative stress in the mouse liver upon deletion of catechol O-methyltransferase. <i>Biochemical Pharmacology</i> , 2009, 77, 1541-1552.	4.4	18
65	Expression of tyrosine hydroxylase in the striatum of atipamezole-treated rats. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 36, 602-604.	4.0	1
66	Importance of membrane-bound catechol-O-methyltransferase in L-DOPA metabolism: a pharmacokinetic study in two types of <i>Comt</i> gene modified mice. <i>British Journal of Pharmacology</i> , 2009, 158, 1884-1894.	5.4	21
67	Combination of snap freezing, differential pH two-dimensional reverse-phase high-performance liquid chromatography, and iTRAQ technology for the peptidomic analysis of the effect of prolyl oligopeptidase inhibition in the rat brain. <i>Analytical Biochemistry</i> , 2009, 393, 80-87.	2.4	24
68	Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. <i>Experimental Neurology</i> , 2009, 219, 499-506.	4.1	35
69	Localization of prolyl oligopeptidase in the thalamic and cortical projection neurons: A retrograde neurotracing study in the rat brain. <i>Neuroscience Letters</i> , 2009, 450, 201-205.	2.1	9
70	The multiple faces of quercetin in neuroprotection. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 397-409.	2.4	126
71	Molecular dynamics study of prolyl oligopeptidase with inhibitor in binding cavity. SAR and QSAR in <i>Environmental Research</i> , 2009, 20, 595-609.	2.2	10
72	Enzymatic detoxification of gluten by germinating wheat proteases: Implications for new treatment of celiac disease. <i>Annals of Medicine</i> , 2009, 41, 390-400.	3.8	50

#	ARTICLE	IF	CITATIONS
73	L-Dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats. <i>NeuroReport</i> , 2009, 20, 313-318.	1.2	0
74	Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. <i>Histochemistry and Cell Biology</i> , 2008, 130, 993-1003.	1.7	58
75	Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. <i>Journal of Comparative Neurology</i> , 2008, 507, 1694-1708.	1.6	47
76	Time-dependent protective and harmful effects of quercetin on 6-OHDA-induced toxicity in neuronal SH-SY5Y cells. <i>Toxicology</i> , 2008, 250, 1-8.	4.2	39
77	Characterization of membrane-bound prolyl endopeptidase from brain. <i>FEBS Journal</i> , 2008, 275, 4415-4427.	4.7	28
78	Serotonergic Activation after 2-Week Intrastratial Infusion of L-Dopa and Slow Recovery of Circling in Rats with Unilateral Nigral Lesions. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 102, 300-307.	2.5	9
79	Increase in Free Choice Oral Ethanol Self-Administration in Catechol-O-Methyltransferase Gene-Disrupted Male Mice. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 297-304.	2.5	18
80	Stress-Induced Analgesia and Morphine Responses Are Changed in Catechol-O-Methyltransferase-Deficient Male Mice. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 367-373.	2.5	22
81	Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures. <i>Brain Research</i> , 2008, 1203, 149-159.	2.2	42
82	Effect of forced chronic oral nicotine exposure on intravenous self-administration and rewarding properties of acute nicotine. <i>European Journal of Pharmacology</i> , 2008, 591, 164-170.	3.5	11
83	Spatial association of prolyl oligopeptidase, inositol 1,4,5-triphosphate type 1 receptor, substance P and its neurokinin-1 receptor in the rat brain: An immunohistochemical colocalization study. <i>Neuroscience</i> , 2008, 153, 1177-1189.	2.3	24
84	Expression and traffic of cellular prolyl oligopeptidase are regulated during cerebellar granule cell differentiation, maturation, and aging. <i>Neuroscience</i> , 2008, 156, 580-585.	2.3	36
85	Different viabilities and toxicity types after 6-OHDA and Ara-C exposure evaluated by four assays in five cell lines. <i>Toxicology in Vitro</i> , 2008, 22, 182-189.	2.4	22
86	Site-Specific Role of Catechol-O-Methyltransferase in Dopamine Overflow within Prefrontal Cortex and Dorsal Striatum. <i>Journal of Neuroscience</i> , 2007, 27, 10196-10209.	3.6	244
87	Deficient activity of mammalian prolyl oligopeptidase on the immunoactive peptide digestion in coeliac disease. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 562-571.	1.5	21
88	Pharmacologically Diverse Antidepressants Rapidly Activate Brain-Derived Neurotrophic Factor Receptor TrkB and Induce Phospholipase-C β Signaling Pathways in Mouse Brain. <i>Neuropsychopharmacology</i> , 2007, 32, 2152-2162.	5.4	277
89	2(S)-(Cycloalk-1-enecarbonyl)-1-(4-phenyl-butanoyl)pyrrolidines and 2(S)-(aroyl)-1-(4-phenylbutanoyl)pyrrolidines as prolyl oligopeptidase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 2024-2031.	3.0	17
90	Comparison of the Effects of Deramciclone, Ritanserin and Buspirone on Extracellular Dopamine and Its Metabolites in Striatum and Nucleus Accumbens of Freely Moving Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2007, 102, 071027162142001-???	2.5	9

#	ARTICLE	IF	CITATIONS
91	Transcriptional profiling of C57 and DBA strains of mice in the absence and presence of morphine. <i>BMC Genomics</i> , 2007, 8, 76.	2.8	39
92	Intracerebroventricular antisense knockdown of GÎ±i2 results in ciliary stasis and ventricular dilatation in the rat. <i>BMC Neuroscience</i> , 2007, 8, 26.	1.9	17
93	On the role of prolyl oligopeptidase in health and disease. <i>Neuropeptides</i> , 2007, 41, 1-24.	2.2	210
94	Distribution of Immunoreactive Prolyl Oligopeptidase in Human and Rat Brain. <i>Neurochemical Research</i> , 2007, 32, 1365-1374.	3.3	50
95	Prolyl Oligopeptidase: A Potential Target for the Treatment of Cognitive Disorders. <i>Drug News and Perspectives</i> , 2007, 20, 293.	1.5	98
96	A prolyl oligopeptidase inhibitor, Z-Pro-Proline, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine. <i>Toxicology in Vitro</i> , 2006, 20, 1446-1454.	2.4	32
97	Beneficial Effect of Prolyl Oligopeptidase Inhibition on Spatial Memory in Young but Not in Old Scopolamine-Treated Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 100, 061214140717002-???	2.5	35
98	An introduction of a pyridine group into the structure of prolyl oligopeptidase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5590-5593.	2.2	9
99	Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. <i>Biochemical Pharmacology</i> , 2006, 71, 683-692.	4.4	56
100	Synthesis and biological evaluation of 6/7-exo-methyl-3Î²-(4-iodo)phenyltropane-2Î²-carboxylic acid methyl esters. <i>European Journal of Medicinal Chemistry</i> , 2005, 40, 299-304.	5.5	2
101	The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 24, 503-511.	4.0	21
102	Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells. <i>Brain Research</i> , 2005, 1038, 83-91.	2.2	14
103	Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human Î±-synuclein. <i>Neurobiology of Disease</i> , 2005, 20, 303-313.	4.4	93
104	Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 3513-3518.	7.1	335
105	Synthesis and Characterization of the Novel Fluorescent Prolyl Oligopeptidase Inhibitor 4-Fluoresceinthiocarbamoyl- 6-aminocaproyl-L-prolyl-2(S)-(Hydroxy- acetyl)pyrrolidine. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7093-7095.	6.4	10
106	Dicarboxylic Acid Azacycle-Prolyl-pyrrolidine Amides as Prolyl Oligopeptidase Inhibitors and Three-Dimensional Quantitative Structure-Activity Relationship of the Enzyme-Inhibitor Interactions. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4772-4782.	6.4	14
107	Evolutionary relationships of the prolyl oligopeptidase family enzymes. <i>FEBS Journal</i> , 2004, 271, 2705-2715.	0.2	79
108	Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004, 370, 279-289.	3.0	11

#	ARTICLE	IF	CITATIONS
109	d-Amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. <i>Psychopharmacology</i> , 2004, 172, 1-10.	3.1	56
110	Synergism in gene delivery by small PEIs and three different nonviral vectors. <i>International Journal of Pharmaceutics</i> , 2004, 270, 175-184.	5.2	54
111	Effect of cell-surface glycosaminoglycans on cationic carrier combined with low-MW PEI-mediated gene transfection. <i>International Journal of Pharmaceutics</i> , 2004, 284, 43-52.	5.2	10
112	A Cyclopent-2-enecarbonyl Group Mimics Proline at the P2 Position of Prolyl Oligopeptidase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 5605-5607.	6.4	62
113	The roles of dopamine transporter and Bcl-2 protein in the protection of CV1-P cells from 6-OHDA-induced toxicity. <i>Toxicology Letters</i> , 2004, 154, 117-123.	0.8	20
114	Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site. <i>Biochemical Journal</i> , 2004, 382, 1003-1008.	3.7	20
115	Increased p53 levels without caspase-3 activity and change of cell viability in 6-hydroxydopamine-treated CV1-P cells. <i>Cell Biology and Toxicology</i> , 2003, 19, 177-187.	5.3	8
116	Effects of aqueous extracts of <i>Halimeda incrassata</i> (Ellis) Lamouroux and <i>Bryothamnion triquetrum</i> (S.G.Gmelim) Howe on hydrogen peroxide and methyl mercury-induced oxidative stress in GT1-7 mouse hypothalamic immortalized cells. <i>Phytomedicine</i> , 2003, 10, 39-47.	5.3	41
117	Production of functional recombinant tyrosine hydroxylase by the BPV-1 expression plasmids in the cell cultures. <i>Plasmid</i> , 2003, 50, 230-235.	1.4	4
118	Atipamezole, an α_2 -adrenoceptor antagonist, augments the effects of l-DOPA on evoked dopamine release in rat striatum. <i>European Journal of Pharmacology</i> , 2003, 462, 83-89.	3.5	28
119	Different synergistic roles of small polyethylenimine and Dosper in gene delivery. <i>Journal of Controlled Release</i> , 2003, 88, 173-183.	9.9	46
120	Tissue histopathology, clinical chemistry and behaviour of adult comt-gene-disrupted mice. <i>Journal of Applied Toxicology</i> , 2003, 23, 213-219.	2.8	31
121	Conformationally rigid N-acyl-5-alkyl-l-prolyl-pyrrolidines as prolyl oligopeptidase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 3611-3619.	3.0	23
122	Agonists for neuropeptide Y receptors Y1 and Y5 stimulate different phases of feeding in guinea pigs. <i>British Journal of Pharmacology</i> , 2003, 139, 1433-1440.	5.4	40
123	New Prolyl Oligopeptidase Inhibitors Developed from Dicarboxylic Acid Bis(l-prolyl-pyrrolidine) Amides. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 4543-4551.	6.4	17
124	Brain histamine and histamine H3 receptors following repeated l-histidine administration in rats. <i>Life Sciences</i> , 2003, 73, 1491-1503.	4.3	9
125	Pharmacokinetics and Pharmacodynamics of Entacapone and Tolcapone after Acute and Repeated Administration: A Comparative Study in the Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 498-506.	2.5	50
126	Ara-C induces apoptosis in monkey fibroblast cells. <i>Toxicology in Vitro</i> , 2003, 17, 367-373.	2.4	17

#	ARTICLE	IF	CITATIONS
127	Entacapone protects from angiotensin II-induced inflammation and renal injury. <i>Journal of Hypertension</i> , 2003, 21, 2353-2363.	0.5	19
128	Resistance to salt-induced hypertension in catechol-O-methyltransferase-gene-disrupted mice. <i>Journal of Hypertension</i> , 2003, 21, 2365-2374.	0.5	33
129	Effect of Dopamine Uptake Inhibition on Brain Catecholamine Levels and Locomotion in Catechol-O-methyltransferase-Disrupted Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 303, 1309-1316.	2.5	79
130	Dicarboxylic Acidbis(l-Prolyl-pyrrolidine) Amides as Prolyl Oligopeptidase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 4581-4584.	6.4	36
131	Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819. <i>Biochemical Pharmacology</i> , 2002, 64, 463-471.	4.4	51
132	The use of low-molecular-weight PEIs as gene carriers in the monkey fibroblastoma and rabbit smooth muscle cell cultures. <i>Journal of Gene Medicine</i> , 2002, 4, 205-214.	2.8	34
133	Pharmacodynamic Response of Entacapone in Rats after Administration of Entacapone Formulations and Prodrugs with Varying Bioavailabilities. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2002, 90, 327-332.	0.0	3
134	Brain catecholamine metabolism in catechol-O-methyltransferase (COMT) deficient mice. <i>European Journal of Neuroscience</i> , 2002, 15, 246-256.	2.6	166
135	4-Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-1-prolyl-2(S)-acylpyrrolidines as prolyl oligopeptidase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 2199-2206.	3.0	36
136	Adaptations to iron deficiency: cardiac functional responsiveness to norepinephrine, arterial remodeling, and the effect of beta-blockade on cardiac hypertrophy. <i>BMC Physiology</i> , 2002, 2, 1.	3.6	42
137	Reduced natriuretic response to acute sodium loading in COMT gene deleted mice. <i>BMC Physiology</i> , 2002, 2, 14.	3.6	13
138	Receptor subtypes Y1 and Y5 mediate neuropeptide Y induced feeding in the guinea-pig. <i>British Journal of Pharmacology</i> , 2002, 135, 2029-2037.	5.4	58
139	Catecholamine metabolism in the brain by membrane-bound and soluble catechol-o-methyltransferase (COMT) estimated by enzyme kinetic values. <i>Medical Hypotheses</i> , 2001, 57, 628-632.	1.5	31
140	Brain prolyl oligopeptidase activity is associated with neuronal damage rather than β -amyloid accumulation. <i>NeuroReport</i> , 2001, 12, 3309-3312.	1.2	28
141	Cholecystokinin 2 receptor-deficient mice display altered function of brain dopaminergic system. <i>Psychopharmacology</i> , 2001, 158, 198-204.	3.1	30
142	The role of dopamine-metabolizing enzymes in the regulation of renal sodium excretion in the rat. <i>Pflügers Archiv European Journal of Physiology</i> , 2001, 442, 505-510.	2.8	12
143	Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats. <i>Journal of Neuroscience Methods</i> , 2001, 109, 47-52.	2.5	9
144	Quantitation of entacapone glucuronide in rat plasma by on-line coupled restricted access media column and liquid chromatography-tandem mass spectrometry. <i>Biomedical Applications</i> , 2001, 759, 227-236.	1.7	26

#	ARTICLE	IF	CITATIONS
145	Efficient Transfection of Novel Bovine Papillomavirus 1 Expression Plasmids. <i>Plasmid</i> , 2001, 46, 163-169.	1.4	10
146	Effects of aqueous solubility and dissolution characteristics on oral bioavailability of entacapone. <i>Drug Development Research</i> , 2000, 49, 238-244.	2.9	22
147	Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats. <i>European Journal of Neuroscience</i> , 2000, 12, 3823-3832.	2.6	60
148	An acute i.c.v. infusion of leptin has no effect on hypothalamic histamine and tele-methylhistamine contents in Wistar rats. <i>European Journal of Pharmacology</i> , 2000, 395, 113-119.	3.5	14
149	Effects of histamine H3-ligands on the levodopa-induced turning behavior of hemiparkinsonian rats. <i>Parkinsonism and Related Disorders</i> , 2000, 6, 159-164.	2.2	26
150	Activation of 5-HT2A receptors impairs response control of rats in a five-choice serial reaction time task. <i>Neuropharmacology</i> , 2000, 39, 471-481.	4.1	97
151	Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone. <i>Life Sciences</i> , 2000, 67, 205-216.	4.3	29
152	Regional distribution of histamine H3 receptor binding sites in rat brain following L-histidine loading – an autoradiography study. <i>Inflammation Research</i> , 2000, 49, 47-48.	4.0	1
153	Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. <i>Journal of Psychiatry and Neuroscience</i> , 2000, 25, 33-42.	2.4	33
154	Effects of Repeated Low Dose Administration and Withdrawal of Haloperidol on Sexual Behaviour of Male Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999, 84, 292-295.	0.0	1
155	Microdialysis Studies on the Action of Tolcapone on Pharmacologically Elevated Extracellular Dopamine Levels in Conscious Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999, 85, 233-238.	0.0	26
156	Histamine H 3 receptor binding sites in rat cortex following L-histidine loading. <i>Inflammation Research</i> , 1999, 48, 59-60.	4.0	3
157	Hypothalamic histamine, growth rate, plasma prolactin and growth hormone levels in rats with long-term portacaval anastomosis. <i>Inflammation Research</i> , 1999, 48, 81-85.	4.0	7
158	Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake. <i>European Journal of Pharmacology</i> , 1999, 370, 125-131.	3.5	40
159	Catechol-O-methyltransferase activity in rat brain primary neuronal and glial cell cultures and its inhibition by novel drugs. <i>Neuroscience Research Communications</i> , 1999, 25, 71-77.	0.2	2
160	Apomorphine-induced behavioural sensitization in rats: individual differences, role of dopamine and NMDA receptors. <i>European Neuropsychopharmacology</i> , 1999, 9, 507-514.	0.7	19
161	Synthesis and in Vitro Pharmacology of a Series of New Chiral Histamine H3-Receptor Ligands: 2-(R and) Tj ETQq1 1 0.784314 rgBT 1193-1202.	6.4	33
162	CATECHOL O-METHYLTRANSFERASE. , 1999, , 55-91.		5

#	ARTICLE	IF	CITATIONS
163	Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. <i>Pharmacological Reviews</i> , 1999, 51, 593-628.	16.0	752
164	Lack of Effect of Leptin on the Behaviour of Mice Predicting the Level of Anxiety and Depression. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1998, 83, 139-142.	0.0	7
165	L-Arginine abolishes the anxiolytic-like effect of diazepam in the elevated plus-maze test in rats. <i>European Journal of Pharmacology</i> , 1998, 351, 287-290.	3.5	37
166	No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats. <i>European Journal of Pharmacology</i> , 1998, 356, 127-137.	3.5	30
167	Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze. <i>Neuropeptides</i> , 1998, 32, 235-240.	2.2	16
168	Effect of subchronic administration of tolcapone on L-DOPA-and carbidopa-induced release of striatal dopamine and its metabolites. <i>Bulletin of Experimental Biology and Medicine</i> , 1998, 125, 145-147.	0.8	1
169	Deramciclone, a putative anxiolytic drug, is a serotonin 5-HT 2C receptor inverse agonist but fails to induce 5-HT 2C receptor down-regulation. <i>Psychopharmacology</i> , 1998, 136, 99-104.	3.1	33
170	Different renal effects of two inhibitors of catechol-O-methylation in the rat: Entacapone and CGP 28014. <i>Acta Physiologica Scandinavica</i> , 1998, 162, 489-494.	2.2	18
171	Optimization of the Hydrolysis of Conjugated L-DOPA, Dopamine and Dihydroxyphenylacetic Acid in Human Urine for Assay by High-Performance Liquid Chromatography with Electrochemical Detection. <i>Clinical Chemistry and Laboratory Medicine</i> , 1997, 35, 229-35.	2.3	2
172	Catechol O-Methyltransferase: Characterization of the Protein, Its Gene, and the Preclinical Pharmacology of COMT Inhibitors. <i>Advances in Pharmacology</i> , 1997, 42, 324-328.	2.0	15
173	Relation of exploratory behavior of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. <i>European Neuropsychopharmacology</i> , 1997, 7, 289-294.	0.7	18
174	Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats. <i>Behavioural Brain Research</i> , 1997, 86, 49-57.	2.2	28
175	Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. <i>Behavioural Brain Research</i> , 1997, 82, 195-202.	2.2	64
176	Increase of catechol-O-methyltransferase activity in rat brain microglia after intrastriatal infusion of fluorocitrate, a glial toxin. <i>Neuroscience Letters</i> , 1997, 230, 155-158.	2.1	19
177	Overflow of noradrenaline and dopamine in frontal cortex after [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine] (DSP-4) treatment: in vivo microdialysis study in anaesthetized rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1997, 355, 267-272.	3.0	46
178	7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety. <i>Psychopharmacology</i> , 1997, 131, 399-405.	3.1	125
179	Receptor binding profile and anxiolytic-type activity of deramciclone (EGIS-3886) in animal models. <i>Drug Development Research</i> , 1997, 40, 333-348.	2.9	34
180	Tolcapone. <i>CNS Drugs</i> , 1996, 5, 482.	5.9	0

#	ARTICLE	IF	CITATIONS
181	Evidence for cholecystokininA receptors in bovine adrenal chromaffin cells. <i>NeuroReport</i> , 1996, 7, 2167-2170.	1.2	4
182	Nitric oxide mediates caerulein-induced suppression of locomotor activity. <i>Neuropeptides</i> , 1996, 30, 323-326.	2.2	3
183	Morphine Withdrawal Alters Anterior Pituitary Hormone Secretion, Brain Endopeptidase Activity and Brain Monoamine Metabolism in the Rat. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996, 78, 129-135.	0.0	8
184	Neuroendocrine Effects of Dexmedetomidine: Evidence of Cross-Tolerance Between a μ -Opioid Agonist and an α_2 -Adrenoceptor Agonist in Growth Hormone Secretion of the Male Rat. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996, 78, 136-142.	0.0	3
185	Minor Effect of Tolcapone, a Catechol-O-Methyltransferase Inhibitor, on Extracellular Dopamine Levels Modified by Amphetamine or Pargyline: A Microdialysis Study in Anaesthetized Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996, 78, 392-396.	0.0	17
186	Neurochemical Mediators of Anxiety have Inconsistent Effects on Hypothalamic Self-Stimulation in Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996, 78, 354-360.	0.0	7
187	Validation of assay of catechol-O-methyltransferase activity in human erythrocytes. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1996, 14, 515-523.	2.8	23
188	Effect of modified brain histamine contents on prolactin and thyrotropin secretion in male rats. <i>European Journal of Endocrinology</i> , 1996, 134, 209-214.	3.7	5
189	Effect of Entacapone, a COMT Inhibitor, on the Pharmacokinetics and Metabolism of Levodopa After Administration of Controlled-Release Levodopa-Carbidopa in Volunteers. <i>Clinical Neuropharmacology</i> , 1995, 18, 46-57.	0.7	53
190	Tolcapone, an inhibitor of catechol: O-methyltransferase, counteracts memory deficits caused by bilateral cholinotoxin lesions of the basal nuclei of Meynert. <i>NeuroReport</i> , 1995, 6, 1219-1222.	1.2	13
191	Inhibition of nitric oxide synthase causes anxiolytic-like behaviour in an elevated plus-maze. <i>NeuroReport</i> , 1995, 6, 1413-1416.	1.2	77
192	Opposite Effect of Ethanol on Recombinant Membrane-Bound and Soluble Activities of Catechol-O-methyltransferase. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1995, 77, 414-416.	0.0	5
193	Improved assay of reaction products to quantitate catechol-O-methyltransferase activity by high-performance liquid chromatography with electrochemical detection. <i>Biomedical Applications</i> , 1995, 663, 137-142.	1.7	60
194	Further studies on the role of cholecystokinin-A and B receptors in secretion of anterior pituitary hormones in male rats. <i>Neuropeptides</i> , 1995, 28, 1-11.	2.2	7
195	Role of N-methyl-d-aspartic acid and cholecystokinin receptors in apomorphine-induced aggressive behaviour in rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1995, 351, 363-70.	3.0	30
196	Cold exposure attenuates effects of secretagogues on serum prolactin and growth hormone levels in male rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1995, 268, E758-E765.	3.5	3
197	Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and l-dihydroxyphenylalanine in rat models of depression. <i>European Journal of Pharmacology</i> , 1995, 274, 229-233.	3.5	21
198	Differential disappearance of tolerance to thermal, hormonal and locomotor effects of morphine in the male rat. <i>European Journal of Pharmacology</i> , 1995, 285, 69-77.	3.5	12

#	ARTICLE	IF	CITATIONS
199	Î¼- and Î±-opioid receptor antisense oligodeoxynucleotides antagonize morphine-induced growth hormone secretion in rats. <i>European Journal of Pharmacology</i> , 1995, 284, 227-230.	3.5	9
200	Animal Studies on CCK and Anxiety. <i>Neuroscience Intelligence Unit</i> , 1995, , 57-72.	0.5	0
201	Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1994, 349, 478-484.	3.0	30
202	Variation in tolerance to the antinociceptive, hormonal and thermal effects of morphine after a 5-day pre-treatment of male rats with increasing doses of morphine. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1994, 349, 161-9.	3.0	6
203	General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. <i>General Pharmacology</i> , 1994, 25, 813-824.	0.7	114
204	Effects of bilateral cholinotoxin infusions on the behavior and brain biochemistry of the rats. <i>Pharmacology Biochemistry and Behavior</i> , 1994, 49, 33-40.	2.9	12
205	Subdiaphragmatic vagotomy does not prevent the anti-exploratory effect of caerulein in the elevated plus-maze. <i>Neuropeptides</i> , 1994, 26, 39-45.	2.2	8
206	N-Nitro-L-arginine attenuates development of tolerance to antinociceptive but not to hormonal effects of morphine. <i>European Journal of Pharmacology</i> , 1994, 259, 57-64.	3.5	16
207	Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats. <i>British Journal of Pharmacology</i> , 1994, 112, 13-18.	5.4	25
208	Clinical Potential of Catechol-O-Methyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease. <i>CNS Drugs</i> , 1994, 1, 172-179.	5.9	35
209	Amiridine (NIK-247) and cerebrocrast in the alleviation of cholinergic lesion-induced learning deficit in male rats. <i>Drug Development Research</i> , 1993, 30, 219-228.	2.9	3
210	Biogenic amine metabolites in the CSF of patients with late onset and alcoholic ataxias. <i>Acta Neurologica Scandinavica</i> , 1993, 87, 309-311.	2.1	4
211	Social isolation of rats increases the density of cholecystokinin receptors in the frontal cortex and abolishes the anti-exploratory effect of caerulein. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1993, 348, 96-101.	3.0	32
212	Ondansetron, an antagonist of 5-HT ₃ receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze. <i>Psychopharmacology</i> , 1993, 110, 213-218.	3.1	56
213	Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats. <i>European Journal of Pharmacology</i> , 1993, 250, 77-84.	3.5	32
214	Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase. <i>European Journal of Pharmacology</i> , 1993, 239, 39-45.	3.5	16
215	Effect of nitecapone and clorgyline, given intracerebro-ventricularly on L-dopa metabolism in the rat brain. <i>NeuroReport</i> , 1992, 3, 641-644.	1.2	9
216	Different <i>in vivo</i> properties of three new inhibitors of catechol O-methyltransferase in the rat. <i>British Journal of Pharmacology</i> , 1992, 105, 569-574.	5.4	86

#	ARTICLE	IF	CITATIONS
217	Development of tolerance to the hormonal effects of morphine without changes in the aminergic functions in the brain of the rat. <i>Neuropharmacology</i> , 1992, 31, 765-770.	4.1	4
218	Effects of central and peripheral type benzodiazepine ligands on thyrotropin and prolactin secretion. <i>Neuropeptides</i> , 1992, 21, 183-191.	2.2	15
219	Hormone responses to sedative drugs and cold exposure in two rat lines with high and low alcohol sensitivity. <i>Pharmacology Biochemistry and Behavior</i> , 1992, 41, 795-799.	2.9	4
220	Possible role of cholecystokinin-A receptors in regulation of thyrotropin (TSH) secretion in male rats. <i>Neuropeptides</i> , 1992, 23, 251-258.	2.2	14
221	Effects of systemic carbidopa on dopamine synthesis in rat hypothalamus and striatum. <i>Journal of Neural Transmission Parkinson's Disease and Dementia Section</i> , 1992, 4, 143-154.	1.2	12
222	Effects of Central and Peripheral Type Benzodiazepine Ligands on Growth Hormone and Gonadotropin Secretion in Male Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1992, 71, 75-80.	0.0	2
223	Characteristics of catechol O-methyltransferase (COMT) and properties of selective COMT inhibitors. <i>Neuropharmacology</i> , 1992, 39, 291-350.		149
224	Neurochemical and psychomotor interactions of new selective COMT inhibitors with clorgyline and nomifensine in levodopa-treated rats and mice. <i>Archives Internationales De Pharmacodynamie Et De Therapie</i> , 1992, 320, 5-20.	0.2	6
225	Central and peripheral type benzodiazepine ligands displace [³ H][3-Me-His ²]TRH from its binding sites in the brain and the anterior pituitary and antagonize the effect of TRH in the rat duodenum. <i>Neuropeptides</i> , 1991, 19, 147-155.	2.2	5
226	Anterolateral Hypothalamic Deafferentation Inhibits Histamine-Induced Prolactin Secretion and Potentiates TRH-Induced Thyrotropin Secretion in Male Rats. <i>Neuroendocrinology</i> , 1991, 54, 274-278.	2.5	2
227	Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1991, 344, 412-8.	3.0	23
228	Acute Toxicity of Three New Selective COMT Inhibitors in Mice with Special Emphasis on Interactions with Drugs Increasing Catecholaminergic Neurotransmission. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1991, 69, 64-70.	0.0	19
229	Effects of Cysteamine Pretreatment and Hypothalamic Periventricular Nucleus Lesion on the Cold-Stimulated Thyrotropin Responses to Intracerebroventricular 5-Hydroxytryptamine in Male Rats. <i>Journal of Neuroendocrinology</i> , 1990, 2, 485-492.	2.6	0
230	Studies on the contact sensitizing activity of dithranol (anthralin) and 10-butyryl dithranol (butantrone). <i>Contact Dermatitis</i> , 1990, 23, 103-110.	1.4	7
231	Effects of hypothalamic paraventricular nucleus lesion on the cold-stimulated TSH responses to 5-HT in male rats. <i>Acta Physiologica Scandinavica</i> , 1990, 139, 233-240.	2.2	6
232	Rationale for Selective COMT Inhibitors as Adjuncts in the Drug Treatment of Parkinson's Disease. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1990, 66, 317-323.	0.0	127
233	Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats. <i>Journal of Neural Transmission Parkinson's Disease and Dementia Section</i> , 1990, 2, 31-43.	1.2	24
234	Site-Dependent Action of Intracerebroventricular 5-Hydroxytryptamine on the Cold-Stimulated Thyrotropin Secretion in Male Rats. <i>Neuroendocrinology</i> , 1990, 51, 45-50.	2.5	8

#	ARTICLE	IF	CITATIONS
235	Lighting conditions affect serum and pituitary TSH in male rats. American Journal of Physiology - Endocrinology and Metabolism, 1990, 259, E162-E169.	3.5	1
236	Selective cardiorespiratory activity of an iodinated analog of thyrotropin-releasing hormone (TRH). Peptides, 1990, 11, 939-944.	2.4	8
237	Complex actions of serotonergic agonists on cold-stimulated TSH secretion in male rats. European Journal of Pharmacology, 1990, 180, 91-102.	3.5	8
238	Comparison of the Effects of Intraventricular Taurine, GABA and Homotaurine on Serum Prolactin Levels in Male Rats. Basic and Clinical Pharmacology and Toxicology, 1989, 65, 152-156.	0.0	7
239	Target tissue morphology and serum biochemistry following 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure in a TCDD-susceptible and a TCDD-resistant rat strain*1. Fundamental and Applied Toxicology, 1989, 12, 698-712.	1.8	82
240	New selective COMT inhibitors: useful adjuncts for Parkinson's disease?. Trends in Pharmacological Sciences, 1989, 10, 54-56.	8.7	109
241	Somatostatin, neuropeptide Y, GABA and cholinergic enzymes in brain of pentylenetetrazol-kindled rats. Neuropeptides, 1989, 14, 197-207.	2.2	36
242	Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. Journal of Medicinal Chemistry, 1989, 32, 841-846.	6.4	139
243	Target Tissue Morphology and Serum Biochemistry following 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) Exposure in a TCDD-Susceptible and a TCDD-Resistant Rat Strain. Toxicological Sciences, 1989, 12, 698-712.	3.1	1
244	Effect of Erythromycin Acistrate and Erythromycin Stearate on Human Colonic Microflora. Scandinavian Journal of Infectious Diseases, 1989, 21, 717-720.	1.5	4
245	Efficacy of erythromycin acistrate (2'-acetyl erythromycin stearate) and erythromycin stearate in experimental infections in mice. Journal of Pharmacology and Experimental Therapeutics, 1989, 250, 1028-33.	2.5	1
246	Further Studies of Serotonergic Activity in the Regulation of the Cold Stimulated Thyrotropin Secretion in Male Rats. Basic and Clinical Pharmacology and Toxicology, 1988, 63, 65-69.	0.0	10
247	Cholinergic regulation of thyrotropin secretion in male rats. European Journal of Pharmacology, 1988, 157, 117-124.	3.5	2
248	Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. European Journal of Pharmacology, 1988, 153, 263-269.	3.5	107
249	Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sciences, 1988, 43, 1465-1471.	4.3	54
250	Concentrations of erythromycin, 2'-acetyl erythromycin, and their anhydro forms in plasma and tonsillar tissue after repeated dosage of erythromycin stearate and erythromycin acistrate. Antimicrobial Agents and Chemotherapy, 1988, 32, 1019-1024.	3.2	11
251	Antibiotic concentration in suction skin blister fluid and saliva after repeated dosage of erythromycin acistrate and erythromycin base. Journal of Antimicrobial Chemotherapy, 1988, 21, 57-65.	3.0	7
252	Absorption of erythromycin acistrate and erythromycin base in the fasting and non-fasting state. Journal of Antimicrobial Chemotherapy, 1988, 21, 45-55.	3.0	22

#	ARTICLE	IF	CITATIONS
253	Time course of the antibacterial activity of erythromycin stearate and erythromycin acistrate against two <i>Staphylococcus aureus</i> strains in vitro. <i>Journal of Antimicrobial Chemotherapy</i> , 1988, 22, 127-133.	3.0	7
254	Fate of single oral doses of erythromycin acistrate, erythromycin stearate and pelleted erythromycin base analysed by mass-spectrometry in plasma of healthy human volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 1988, 21, 33-43.	3.0	41
255	Tonsillar penetration of erythromycin and its 2'-acetyl ester in patients with chronic tonsillitis. <i>Journal of Antimicrobial Chemotherapy</i> , 1988, 21, 73-84.	3.0	19
256	Comparative liver toxicity of various erythromycin derivatives in animals. <i>Journal of Antimicrobial Chemotherapy</i> , 1988, 21, 9-27.	3.0	57
257	Effect of chronic morphine treatment on thyrotropin and prolactin levels and acute hormone responses in the rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1988, 246, 649-54.	2.5	11
258	Differential effect of tetracaine and bupivacaine on catecholamine and 5-hydroxytryptamine turnover. <i>Pain</i> , 1987, 29, 239-245.	4.2	5
259	Striatal membrane-bound and soluble catechol-O-methyl-transferase after selective neuronal lesions in the rat. <i>Journal of Neural Transmission</i> , 1987, 69, 221-228.	2.8	53
260	Potentialiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase. <i>Journal of Neural Transmission</i> , 1987, 70, 233-240.	2.8	17
261	Effect of Enzyme Induction and Inhibition on the Fate of Metronidazole and Tinidazole in the Rat. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1987, 60, 24-28.	0.0	3
262	Aminergic regulation of neuroendocrinological functions: theoretical background and some clinical examples. <i>Medical Biology</i> , 1987, 65, 121-6.	0.4	4
263	Time relationships and reversal by two indoleamines of the pinealectomy-inhibited thyrotropin secretion in male rats. <i>Medical Biology</i> , 1987, 65, 267-72.	0.4	1
264	Toxicological studies with dithranol and its 10-acyl analogues. <i>Archives of Toxicology</i> , 1986, 59, 180-185.	4.2	11
265	Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 1986, 31, 423-426.	1.9	20
266	A 6-month dermal toxicity test with dithranol and butantrone in miniature swine. <i>Contact Dermatitis</i> , 1986, 15, 1-9.	1.4	6
267	Adrenalectomy modifies the effect of intracerebral histamine on the cold-stimulated TSH secretion in male rats. <i>Agents and Actions</i> , 1986, 18, 479-484.	0.7	0
268	Tumor-producing and skin-irritating activity of dithranol (anthralin) and its 10-acyl analogues in SENCAR mice. <i>Carcinogenesis</i> , 1986, 7, 1755-1760.	2.8	14
269	Pharmacokinetics of sustained-release verapamil after a single administration and at steady state. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1985, 10, 133-138.	1.6	13
270	Concentrations of metronidazole and tinidazole in male genital tissues. <i>Antimicrobial Agents and Chemotherapy</i> , 1985, 28, 812-814.	3.2	23

#	ARTICLE	IF	CITATIONS
271	Studies on the site and mechanism of the inhibitory action of intracerebral histamine on the cold-stimulated thyrotropin secretion in male rats. <i>Brain Research</i> , 1985, 343, 329-335.	2.2	15
272	The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. <i>Acta Neurologica Scandinavica</i> , 1985, 72, 385-391.	2.1	31
273	Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 1984, 26, 69-73.	3.2	17
274	Pharmacokinetics of pipemidic acid in healthy middle-aged volunteers and elderly patients with renal insufficiency. <i>Xenobiotica</i> , 1984, 14, 339-347.	1.1	8
275	Skin irritation by dithranol (anthralin) and its 10-acyl analogues in 3 animal models. <i>Contact Dermatitis</i> , 1984, 10, 140-145.	1.4	17
276	Determination of catechol-O-methyltransferase activity by high-performance liquid chromatography with electrochemical detection. <i>Analytical Biochemistry</i> , 1984, 137, 69-73.	2.4	52
277	Concentrations of metronidazole and tinidazole in female reproductive organs after a single intravenous infusion and after repeated oral administration. <i>Infection</i> , 1984, 12, 197-201.	4.7	19
278	On-line radiochemical assay for monoamine oxidase utilizing high-performance liquid chromatography. <i>Journal of Pharmacological Methods</i> , 1984, 12, 247-254.	0.7	3
279	Dual action of morphine on cold-stimulated thyrotropin secretion in male rats. <i>Life Sciences</i> , 1984, 35, 1101-1107.	4.3	18
280	Tumor-producing activity of dithranol (anthralin) and two of its 10-acyl analogs in the dorsal skin of female NMRI mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1984, 229, 255-60.	2.5	5
281	Studies on the mechanism of the enhanced cold-induced TSH secretion in spontaneously hypertensive rats. <i>Experientia</i> , 1983, 39, 423-424.	1.2	4
282	Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. <i>European Journal of Clinical Pharmacology</i> , 1983, 24, 227-230.	1.9	19
283	Determination of a novel antitussive agent 2,4-dimethyl-6-methoxy-3-(2-methylpiperidyl)-propionaldehyde in plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1983, 278, 225-227.	1.7	3
284	The cold-induced TSH secretion is resistant to alterations in the physicochemical properties of the intracerebral infusions. <i>Journal of Endocrinological Investigation</i> , 1983, 6, 225-228.	3.3	2
285	Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. <i>Antimicrobial Agents and Chemotherapy</i> , 1983, 23, 721-725.	3.2	82
286	Inhibition of the TSH secretion by histamine in male rats. <i>European Journal of Endocrinology</i> , 1983, 103, 88-94.	3.7	17
287	Penetration of Trimethoprim and Sulfadiazine into Sinus Secretion in Acute Maxillary Sinusitis. <i>Chemotherapy</i> , 1983, 29, 174-177.	1.6	2
288	Concentrations of Tinidazole in Breast Milk. <i>Acta Pharmacologica Et Toxicologica</i> , 1983, 53, 254-256.	0.0	10

#	ARTICLE	IF	CITATIONS
289	Central regulation of thyrotropin secretion in rats: methodological aspects, problems and some progress. <i>Medical Biology</i> , 1983, 61, 92-100.	0.4	13
290	Impairing effect of food on ketoconazole absorption. <i>Antimicrobial Agents and Chemotherapy</i> , 1982, 21, 730-733.	3.2	82
291	Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion. <i>Journal of Antimicrobial Chemotherapy</i> , 1982, 9, 461-470.	3.0	15
292	Nitrofurantoin is highly bound to plasma protein. <i>Journal of Antimicrobial Chemotherapy</i> , 1982, 9, 327-328.	3.0	4
293	Pharmacokinetics of methenamine in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 1982, 9, 209-216.	3.0	19
294	Effect of stress and dexamethasone on immunoreactive β -endorphin levels in rat hypothalamus and pineal. <i>Acta Physiologica Scandinavica</i> , 1982, 114, 537-541.	2.2	20
295			

#	ARTICLE	IF	CITATIONS
307	Ampicillin concentrations in serum and bronchial mucosa after ampicillin and bacampicillin. Journal of Antimicrobial Chemotherapy, 1979, 5, 236-238.	3.0	0
308	EFFECTS OF METHYLMERCAPTOIMIDAZOLE (MMI), PROPYLTHIOURACIL (PTU), POTASSIUM PERCHLORATE (KClO ₄) AND POTASSIUM IODIDE (KI) ON THE SERUM CONCENTRATIONS OF THYROTROPIN (TSH) AND THYROID HORMONES IN THE RAT. European Journal of Endocrinology, 1979, 91, 271-281.	3.7	37
309	Effects of acute hypotension and hypertension on serum TSH concentrations in male rats. Acta Physiologica Scandinavica, 1979, 107, 105-107.	2.2	4
310	Diurnal variations of medial basal and anterior hypothalamic thyroliberin [TRH] and serum thyrotropin [TSH] concentrations in male rats. Life Sciences, 1978, 23, 1343-1349.	4.3	26
311	NEUROTRANSMITTER CONTROL OF THYROTROPIN SECRETION IN HYPOTHYROID RATS. European Journal of Endocrinology, 1978, 89, 100-107.	3.7	17
312	EVIDENCE FOR DOPAMINERGIC CONTROL OF THYROTROPIN SECRETION IN THE RAT. Journal of Endocrinology, 1977, 72, 329-335.	2.6	35
313	Absorption of rifampin from various preparations and pharmaceutical forms. Clinical Pharmacology and Therapeutics, 1977, 21, 370-374.	4.7	20
314	Pharmacokinetics of nalidixic acid and oxolinic acid in healthy women. Clinical Pharmacology and Therapeutics, 1976, 19, 37-46.	4.7	20
315	Anesthetics and Thyrotropin Secretion in the Rat. Endocrinology, 1976, 99, 875-880.	2.8	19
316	Plasma Renin Activity and <i>in vitro</i> Synthesis of Aldosterone by the Adrenal Glands of Rats with Spontaneous, Renal, or Pinealectomy-Induced Hypertension. Acta Physiologica Scandinavica, 1975, 94, 184-188.	2.2	27
317	Neurotransmitter control of thyrotropin secretion in the rat. European Journal of Pharmacology, 1975, 30, 221-229.	3.5	79
318	Cross-over study of ten tetracycline preparations. European Journal of Clinical Pharmacology, 1973, 6, 64-68.	1.9	9
319	NEUROTRANSMISSION AND SECRETION OF THYROID-STIMULATING HORMONE. Lancet, The, 1973, 302, 510-511.	13.7	24
320	AMINE UPTAKE AND THYROTROPIN-RELEASING HORMONE. Lancet, The, 1973, 301, 836.	13.7	10
321	Pharmacokinetic Studies with Trimethoprim and Different Doses of Sulfadiazine in Healthy Human Subjects. Chemotherapy, 1973, 19, 289-298.	1.6	31
322	Studies with lithium in euthyrotic, hyperthyrotic and hypothyrotic rats. Life Sciences, 1971, 10, 9-19.	4.3	10
323	The effects of diazepam or diphenhydramine on healthy human subjects. Psychopharmacology, 1971, 21, 202-211.	3.1	43